CINXE.COM

<!DOCTYPE html> <html lang="en" dir="ltr"> <head>  <script async src="https://www.googletagmanager.com/gtag/js?id=G-P63WKM1TM1"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-P63WKM1TM1'); </script>  <script type="text/javascript" > (function(m,e,t,r,i,k,a){m[i]=m[i]||function(){(m[i].a=m[i].a||[]).push(arguments)}; m[i].l=1*new Date(); for (var j = 0; j < document.scripts.length; j++) {if (document.scripts[j].src === r) { return; }} k=e.createElement(t),a=e.getElementsByTagName(t)[0],k.async=1,k.src=r,a.parentNode.insertBefore(k,a)}) (window, document, "script", "https://mc.yandex.ru/metrika/tag.js", "ym"); ym(55165297, "init", { clickmap:false, trackLinks:true, accurateTrackBounce:true, webvisor:false }); </script> <noscript><div><img src="https://mc.yandex.ru/watch/55165297" style="position:absolute; left:-9999px;" alt="" /></div></noscript>    <title>Search results for: leukemia</title> <meta name="description" content="Search results for: leukemia"> <meta name="keywords" content="leukemia"> <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1, maximum-scale=1, user-scalable=no"> <meta charset="utf-8"> <link href="https://cdn.waset.org/favicon.ico" type="image/x-icon" rel="shortcut icon"> <link href="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/css/bootstrap.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/plugins/fontawesome/css/all.min.css" rel="stylesheet"> <link href="https://cdn.waset.org/static/css/site.css?v=150220211555" rel="stylesheet"> </head> <body> <header> <div class="container"> <nav class="navbar navbar-expand-lg navbar-light"> <a class="navbar-brand" href="https://waset.org"> <img src="https://cdn.waset.org/static/images/wasetc.png" alt="Open Science Research Excellence" title="Open Science Research Excellence" /> </a> <button class="d-block d-lg-none navbar-toggler ml-auto" type="button" data-toggle="collapse" data-target="#navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"> <span class="navbar-toggler-icon"></span> </button> <div class="w-100"> <div class="d-none d-lg-flex flex-row-reverse"> <form method="get" action="https://waset.org/search" class="form-inline my-2 my-lg-0"> <input class="form-control mr-sm-2" type="search" placeholder="Search Conferences" value="leukemia" name="q" aria-label="Search"> <button class="btn btn-light my-2 my-sm-0" type="submit"><i class="fas fa-search"></i></button> </form> </div> <div class="collapse navbar-collapse mt-1" id="navbarMenu"> <ul class="navbar-nav ml-auto align-items-center" id="mainNavMenu"> <li class="nav-item"> <a class="nav-link" href="https://waset.org/conferences" title="Conferences in 2024/2025/2026">Conferences</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/disciplines" title="Disciplines">Disciplines</a> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/committees" rel="nofollow">Committees</a> </li> <li class="nav-item dropdown"> <a class="nav-link dropdown-toggle" href="#" id="navbarDropdownPublications" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> Publications </a> <div class="dropdown-menu" aria-labelledby="navbarDropdownPublications"> <a class="dropdown-item" href="https://publications.waset.org/abstracts">Abstracts</a> <a class="dropdown-item" href="https://publications.waset.org">Periodicals</a> <a class="dropdown-item" href="https://publications.waset.org/archive">Archive</a> </div> </li> <li class="nav-item"> <a class="nav-link" href="https://waset.org/page/support" title="Support">Support</a> </li> </ul> </div> </div> </nav> </div> </header> <main> <div class="container mt-4"> <div class="row"> <div class="col-md-9 mx-auto"> <form method="get" action="https://publications.waset.org/abstracts/search"> <div id="custom-search-input"> <div class="input-group"> <i class="fas fa-search"></i> <input type="text" class="search-query" name="q" placeholder="Author, Title, Abstract, Keywords" value="leukemia"> <input type="submit" class="btn_search" value="Search"> </div> </div> </form> </div> </div> <div class="row mt-3"> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Commenced</strong> in January 2007</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Frequency:</strong> Monthly</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Edition:</strong> International</div> </div> </div> <div class="col-sm-3"> <div class="card"> <div class="card-body"><strong>Paper Count:</strong> 87</div> </div> </div> </div> <h1 class="mt-3 mb-3 text-center" style="font-size:1.6rem;">Search results for: leukemia</h1> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">87</span> Inflammatory Cytokine (Interleukin-8): A Diagnostic Marker in Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sandeep%20Pandey">Sandeep Pandey</a>, <a href="https://publications.waset.org/abstracts/search?q=Nimra%20Habib"> Nimra Habib</a>, <a href="https://publications.waset.org/abstracts/search?q=Ranjana%20Singh"> Ranjana Singh</a>, <a href="https://publications.waset.org/abstracts/search?q=Abbas%20Ali%20Mahdi"> Abbas Ali Mahdi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Leukemia is a malignancy of blood that mainly affects children and young adults; while advancement in the early diagnosis will have the potential to improve the outcome of diseases. A wide range of disease including leukemia shows inflammatory signals in their pathogenesis. In a pilot study conducted in our laboratory, 52 people were screened, of which 26 had leukemia and 26 were free from any kind of malignancy. We performed the estimation of the inflammatory cytokine Interleukin-8 and it was found significantly raised in all the leukemia patients concerning healthy volunteers who participated in the study. Flow cytometry had been performed for the confirmation of leukemia and further genomic, and proteomic, analyses of the sample revealed that IL-8 levels showed a positive correlation in patients with leukemia. The results had shown constitutive secretion of interleukin-8 by leukemia cells. So, our finding demonstrated that IL-8 is considered to have a role in the pathogenesis of leukemia, and quantification of IL-8 levels in leukemia conditions might be more useful and feasible in the clinical setting for the prediction of drug responses where it may represent a putative target for innovative diagnostic toward effective therapeutic approaches. However, further research explorations in this area are needed that include a greater number of patients with all different forms of leukemia, and estimating their IL-8 levels may hold the key for the additional predictive values on the recurrence of leukemia and its prognosis. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=T-ALL" title="T-ALL">T-ALL</a>, <a href="https://publications.waset.org/abstracts/search?q=IL-8" title=" IL-8"> IL-8</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia%20pathogenesis" title=" leukemia pathogenesis"> leukemia pathogenesis</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20therapeutics" title=" cancer therapeutics"> cancer therapeutics</a> </p> <a href="https://publications.waset.org/abstracts/172772/inflammatory-cytokine-interleukin-8-a-diagnostic-marker-in-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/172772.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">72</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">86</span> Acute Myeloid Leukemia Relapse in an a Rare form After Treating his Tuberculosis TB</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Sheikha%20Turki%20Alketbi">Sheikha Turki Alketbi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Objectives: 1. Documenting the spontaneous resolution of AML following the initiation of anti-TB therapy. 2. Presenting an uncommon type of relapse in Acute Myeloid Leukemia. 3. Highlighting the role of immune markers in the diagnosis of Leukemia cutis. 4. Exploring and highlighting the possibility of skin relapse as the exclusive manifestation, even when skin involvement is known secondary manifestation in AML. Background: Spontaneous remission of Acute Myeloid Leukemia (AML) is a rare phenomenon that has only been reported in some case reports, usually following severe infections. Some studies have described the occurrence of tuberculosis (TB) infection with AML, usually after starting chemotherapy. Spontaneous resolution of AML after starting anti TB therapy (ATT), without starting chemotherapy has never been described in the literature. Moreover, Leukemia cutis is another rare skin manifestation of Acute Myeloid Leukemia as a result of infiltration of the skin or subcutaneous tissue by leukemic cells, in which can present during, precedes, after or independently of systemic leukemia. Methods: Here, we present a case of a 13-year-old male who presented with fever, weight loss, lethargy, epistaxis, bruising and dry cough and was later diagnosed with AML. Before initiating leukemia treatment, the patient was tested for TB and was found to have active TB infection. His leukemia treatment was postponed to clear the TB infection and he was commenced on ATT. Two months later, repeat blood film and bone marrow biopsy showed resolution of his AML. The patient remained in remission for 1 month, after which he presented with symmetrical blue purple well-defined round indurated plaques on the chest and thighs. Our differentials were leukemia cutis and Kaposi sarcoma. Results: Skin Biopsy with immune markers done, showed a picture of Acute Myeloid Leukemia. Immunohistochemistry (IHC) showed neoplastic cells diffusely and strongly positive for LCA, CD2, CD31, MPO, CD117, Lysozymes and TDT, and moderately positive for CD34, CD99, CD43 and CD6 And patchy for CD68. Ki67 showed 60% proliferation index. They were negative for the remaining markers. This suggested acute myeloid leukemia (AML). Conclusion: In summary, we present a rare case of TB with AML that resolved after treatment of TB with ATT but relapsed later as leukemia cutis. While skin involvement might occur as a secondary manifestation of AML, Skin relapse could be the only one. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Leukemia%20cutis" title="Leukemia cutis">Leukemia cutis</a>, <a href="https://publications.waset.org/abstracts/search?q=Leukemia%20relapse" title=" Leukemia relapse"> Leukemia relapse</a>, <a href="https://publications.waset.org/abstracts/search?q=Acute%20Myeloid%20Leukemia" title=" Acute Myeloid Leukemia"> Acute Myeloid Leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=spontaneous%20resolution%20of%20AML" title=" spontaneous resolution of AML"> spontaneous resolution of AML</a> </p> <a href="https://publications.waset.org/abstracts/181689/acute-myeloid-leukemia-relapse-in-an-a-rare-form-after-treating-his-tuberculosis-tb" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/181689.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">60</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">85</span> Serological Screening of Cytomegalovirus Infection among Sudanese Patients with Leukemia, Breast and Prostate Cancers at Radiation-Isotope Center in Khartoum</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abuelquasim.%20M.%20Hassan">Abuelquasim. M. Hassan</a>, <a href="https://publications.waset.org/abstracts/search?q=Namarig%20.S.%20Mohammed"> Namarig .S. Mohammed</a>, <a href="https://publications.waset.org/abstracts/search?q=Samah%20F.%20Mohammed"> Samah F. Mohammed</a>, <a href="https://publications.waset.org/abstracts/search?q=Wafaa.%20A.%20Mohammed"> Wafaa. A. Mohammed</a>, <a href="https://publications.waset.org/abstracts/search?q=Wafaa%20M.%20Edriss"> Wafaa M. Edriss</a>, <a href="https://publications.waset.org/abstracts/search?q=Amel%20A.%20Ahmed"> Amel A. Ahmed</a>, <a href="https://publications.waset.org/abstracts/search?q=Elfadil%20M.%20Abass"> Elfadil M. Abass</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Cytomegalovirus (CMV), a common virus, usually causes asymptomatic infections in immunocompetent hosts; however, it may lead to serious complications especially in cancer patients. Objectives: This study was conducted to determine the seroprevalence of human cytomegalovirus (HCMV) among leukemia, breast and prostate cancer patients attending at Radiation Isotope-Center-Khartoum (RICK) from April to August 2016. Material and Methods: A total of 91 subjects were included: 30 leukemic, 22 breast cancer and 29 prostate cancer patients.10 of them were healthy and used as control group, serum samples were collected and tested for CMV IgG & IgM using enzyme-linked immune sorbent assay (ELISA). Result: Of the control group, 9/10 (9.9%) were seropositive for CMV IgG and 1/10 (1.09%) were sero positive for IgM. Also, all cancer groups demonstrated presence of IgG antibody classes as: The percentage of positive results in prostate, breast cancer and leukemia were 35.8 %, 37.2%, and 35.3% respectively. Conclusion: There was no significant correlation between leukemia, breast, prostate and HCMV. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=cytomegalovirus" title="cytomegalovirus">cytomegalovirus</a>, <a href="https://publications.waset.org/abstracts/search?q=serodiagnostic" title=" serodiagnostic"> serodiagnostic</a>, <a href="https://publications.waset.org/abstracts/search?q=breast%20cancer" title=" breast cancer"> breast cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a> </p> <a href="https://publications.waset.org/abstracts/57018/serological-screening-of-cytomegalovirus-infection-among-sudanese-patients-with-leukemia-breast-and-prostate-cancers-at-radiation-isotope-center-in-khartoum" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/57018.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">384</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">84</span> Effectiveness of Physiotherapy in Hand Dysfunction of Leukemia Patients with Chronic Musculoskeletal Graft versus Host Disease Post Bone Marrow Transplant</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mohua%20Chatterjee">Mohua Chatterjee</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajib%20De"> Rajib De</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Bone Marrow Transplant (BMT) is often performed to treat patients with various types of leukemia. A majority of these patients develop complications like chronic musculoskeletal GVHD post-BMT where patients get scleroderma, pain and restricted range of motion of joints of hand. If not treated early, it may cause permanent deformity of hand. This study was done to find the effectiveness of physiotherapy in hand dysfunction caused due to chronic musculoskeletal GVHD of leukemia patients after BMT. Methodology: 23 patients diagnosed with leukemia and having musculoskeletal GVHD were treated with a set of exercises including active exercises and stretching. The outcome was measured by Cochin Hand Function Scale (CHFS) at baseline and after four weeks of intervention. Results: Two patients were not able to carry out exercises beyond two weeks due to relapse of disease and one patient defaulted. It was found that all the patients who received physiotherapy had significant improvement in hand function. Mean CHFS decreased from 63.67 to 27.43 (P value < 0.001) indicating improvement in hand function after four weeks of physiotherapy. Conclusion: Early intervention of physiotherapy is effective in reducing hand dysfunction of leukemia patients with musculoskeletal GVHD post-BMT. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=bone%20marrow%20transplant" title="bone marrow transplant">bone marrow transplant</a>, <a href="https://publications.waset.org/abstracts/search?q=hand%20dysfunction" title=" hand dysfunction"> hand dysfunction</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=musculoskeletal%20graft%20versus%20host%20disease" title=" musculoskeletal graft versus host disease"> musculoskeletal graft versus host disease</a>, <a href="https://publications.waset.org/abstracts/search?q=physiotherapy" title=" physiotherapy"> physiotherapy</a> </p> <a href="https://publications.waset.org/abstracts/55201/effectiveness-of-physiotherapy-in-hand-dysfunction-of-leukemia-patients-with-chronic-musculoskeletal-graft-versus-host-disease-post-bone-marrow-transplant" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/55201.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">240</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">83</span> Spontaneous Tumour Lysis in Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rojith%20K.%20Balakrishnan">Rojith K. Balakrishnan</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Spontaneous tumour lysis syndrome is a constellation of electrolyte abnormalities and an acute renal failure which occurs in the setting of rapid cell turnover prior to the administration of cytotoxic chemotherapy. While spontaneous tumour lysis well-described in patients with Burkitt lymphoma, it is thought to occur less commonly in patients with other hematological malignancies. We present a case of forty-year-old female who presented with features of acute renal failure, on further evaluation turned out to be a newly diagnosed acute myeloid leukemia with spontaneous tumour lysis best of our knowledge only three cases of AML with spontaneous tumour lysis has reported world wide. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=AML" title="AML">AML</a>, <a href="https://publications.waset.org/abstracts/search?q=tumour%20lysis" title=" tumour lysis"> tumour lysis</a>, <a href="https://publications.waset.org/abstracts/search?q=renal%20failure" title=" renal failure"> renal failure</a>, <a href="https://publications.waset.org/abstracts/search?q=myeloid%20leukemia" title=" myeloid leukemia"> myeloid leukemia</a> </p> <a href="https://publications.waset.org/abstracts/28705/spontaneous-tumour-lysis-in-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/28705.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">294</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">82</span> Bacillus cereus Bacteremia and Multi-Organ Failure With Diffuse Brain Hypoxia During Acute Lymphoblastic Leukemia Induction Therapy. A Case Report</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Roni%20Rachel%20Mendelson">Roni Rachel Mendelson</a>, <a href="https://publications.waset.org/abstracts/search?q=Caileigh%20Pudela"> Caileigh Pudela</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Bacillus cereus is a toxin-producing, facultatively anaerobic gram-positive bacterium that is widely distributed environmentally. It can quickly multiply at room temperature with an abundantly present preformed toxin. When ingested, this toxin can cause gastrointestinal illness, which is the commonly known manifestation of the disease. Bacillus cereus sepsis is a disease that is mostly concerning in the population of the immunocompromised patients. One of them is acute lymphoblastic leukemia’s patients during induction. Pediatric acute lymphoblastic leukemia is a common pediatric hematologic malignancy. It is characterized by the rapid proliferation of poorly differentiated lymphoid progenitor cells inside the bone marrow. We present here a 21-month-old boy undergoing induction chemotherapy for acute lymphoblastic leukemia who developed bacillus sepsis bacteremia and, as a result, multi organ failure leading to seizures and multiple strokes. Our case report highlights the extensive overall and neurological damage that can be caused because of bacillus cereus bacteremia, which can lead to higher mortality rate and decreased in survivorship in a highly curable disease. It is very subtle and difficult to recognize and appears to be deteriorating extremely fast. There should be a low threshold for work up and empiric coverage for neutropenic patients during acute lymphoblastic leukemia induction therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20lymphoblastic%20leukemia" title="acute lymphoblastic leukemia">acute lymphoblastic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=bacillus%20cereus" title=" bacillus cereus"> bacillus cereus</a>, <a href="https://publications.waset.org/abstracts/search?q=immunocompromised" title=" immunocompromised"> immunocompromised</a>, <a href="https://publications.waset.org/abstracts/search?q=sepsis" title=" sepsis"> sepsis</a> </p> <a href="https://publications.waset.org/abstracts/165208/bacillus-cereus-bacteremia-and-multi-organ-failure-with-diffuse-brain-hypoxia-during-acute-lymphoblastic-leukemia-induction-therapy-a-case-report" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/165208.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">80</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">81</span> Molecular Detection of mRNA bcr-abl and Circulating Leukemic Stem Cells CD34+ in Patients with Acute Lymphoblastic Leukemia and Chronic Myeloid Leukemia and Its Association with Clinical Parameters</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=B.%20Gonzalez-Yebra">B. Gonzalez-Yebra</a>, <a href="https://publications.waset.org/abstracts/search?q=H.%20Barajas"> H. Barajas</a>, <a href="https://publications.waset.org/abstracts/search?q=P.%20Palomares"> P. Palomares</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Hernandez"> M. Hernandez</a>, <a href="https://publications.waset.org/abstracts/search?q=O.%20Torres"> O. Torres</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Ayala"> M. Ayala</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20L.%20Gonz%C3%A1lez"> A. L. González</a>, <a href="https://publications.waset.org/abstracts/search?q=G.%20Vazquez-Ortiz"> G. Vazquez-Ortiz</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20L.%20Guzman"> M. L. Guzman</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Leukemia arises by molecular alterations of the normal hematopoietic stem cell (HSC) transforming it into a leukemic stem cell (LSC) with high cell proliferation, self-renewal, and cell differentiation. Chronic myeloid leukemia (CML) originates from an LSC-leading to elevated proliferation of myeloid cells and acute lymphoblastic leukemia (ALL) originates from an LSC development leading to elevated proliferation of lymphoid cells. In both cases, LSC can be identified by multicolor flow cytometry using several antibodies. However, to date, LSC levels in peripheral blood (PB) are not established well enough in ALL and CML patients. On the other hand, the detection of the minimal residue disease (MRD) in leukemia is mainly based on the identification of the mRNA bcr-abl gene in CML patients and some other genes in ALL patients. There is no a properly biomarker to detect MDR in both types of leukemia. The objective of this study was to determine mRNA bcr-abl and the percentage of LSC in peripheral blood of patients with CML and ALL and identify a possible association between the amount of LSC in PB and clinical data. We included in this study 19 patients with Leukemia. A PB sample was collected per patient and leukocytes were obtained by Ficoll gradient. The immunophenotype for LSC CD34+ was done by flow cytometry analysis with CD33, CD2, CD14, CD16, CD64, HLA-DR, CD13, CD15, CD19, CD10, CD20, CD34, CD38, CD71, CD90, CD117, CD123 monoclonal antibodies. In addition, to identify the presence of the mRNA bcr-abl by RT-PCR, the RNA was isolated using TRIZOL reagent. Molecular (presence of mRNA bcr-abl and LSC CD34+) and clinical results were analyzed with descriptive statistics and a multiple regression analysis was performed to determine statistically significant association. In total, 19 patients (8 patients with ALL and 11 patients with CML) were analyzed, 9 patients with de novo leukemia (ALL = 6 and CML = 3) and 10 under treatment (ALL = 5 and CML = 5). The overall frequency of mRNA bcr-abl was 31% (6/19), and it was negative in ALL patients and positive in 80% in CML patients. On the other hand, LSC was determined in 16/19 leukemia patients (%LSC= 0.02-17.3). The Novo patients had higher percentage of LSC (0.26 to 17.3%) than patients under treatment (0 to 5.93%). The amount of LSC was significantly associated with the amount of LSC were: absence of treatment, the absence of splenomegaly, and a lower number of leukocytes, negative association for the clinical variables age, sex, blasts, and mRNA bcr-abl. In conclusion, patients with de novo leukemia had a higher percentage of circulating LSC than patients under treatment, and it was associated with clinical parameters as lack of treatment, absence of splenomegaly and a lower number of leukocytes. The mRNA bcr-abl detection was only possible in the series of patients with CML, and molecular detection of LSC could be identified in the peripheral blood of all leukemia patients, we believe the identification of circulating LSC may be used as biomarker for the detection of the MRD in leukemia patients. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=stem%20cells" title="stem cells">stem cells</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=biomarkers" title=" biomarkers"> biomarkers</a>, <a href="https://publications.waset.org/abstracts/search?q=flow%20cytometry" title=" flow cytometry"> flow cytometry</a> </p> <a href="https://publications.waset.org/abstracts/14475/molecular-detection-of-mrna-bcr-abl-and-circulating-leukemic-stem-cells-cd34-in-patients-with-acute-lymphoblastic-leukemia-and-chronic-myeloid-leukemia-and-its-association-with-clinical-parameters" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/14475.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">357</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">80</span> Comparison of Psychological Well-Being, Hope, and Health Concern in Leukemia Patients before and After Receiving Stem Cells</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Tahereh%20Yavari">Tahereh Yavari</a>, <a href="https://publications.waset.org/abstracts/search?q=Sara%20Norozi%20Far"> Sara Norozi Far</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The aim of this study was to compare psychological well-being, hope, and health concerns in leukemia patients before and after receiving stem cells. The statistical population of the present study was made up of leukemia patients in Tehran, and the research sample was among the patients referred to the Bone Marrow Transplant Center of Shariati Hospital in Tehran, and they were placed in two experimental and control groups (15 people in each group), which were selected by purposive sampling method. In order to collect the data for the research, three psychological well-being questionnaires were used by Riff (2002), Schneider's Hope Scale (SHS), and Schneider's Health Concern Questionnaire (HCQ). In order to analyze the data in this research, according to the "pre-test-post-test design with a control group," covariance analysis was used. Based on the research findings, it was concluded that receiving stem cells increases hope and psychological well-being in leukemia patients and significantly reduces health concerns. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=psychological%20well-being" title="psychological well-being">psychological well-being</a>, <a href="https://publications.waset.org/abstracts/search?q=hope" title=" hope"> hope</a>, <a href="https://publications.waset.org/abstracts/search?q=health%20concerns" title=" health concerns"> health concerns</a>, <a href="https://publications.waset.org/abstracts/search?q=blood%20cancer" title=" blood cancer"> blood cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=stem%20cells" title=" stem cells"> stem cells</a> </p> <a href="https://publications.waset.org/abstracts/153809/comparison-of-psychological-well-being-hope-and-health-concern-in-leukemia-patients-before-and-after-receiving-stem-cells" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/153809.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">89</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">79</span> Feasibility of Leukemia Cancer Treatment (K562) by Atmospheric Pressure Plasma Jet</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Mashayekh%20Amir%20Shahriar">Mashayekh Amir Shahriar</a>, <a href="https://publications.waset.org/abstracts/search?q=Akhlaghi%20Morteza"> Akhlaghi Morteza</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajaee%20Hajar"> Rajaee Hajar</a>, <a href="https://publications.waset.org/abstracts/search?q=Khani%20Mohammad%20Reza"> Khani Mohammad Reza</a>, <a href="https://publications.waset.org/abstracts/search?q=Shokri%20Babak"> Shokri Babak</a> </p> <p class="card-text"><strong>Abstract:</strong></p> A new and novel approach in medicine is the use of cold plasma for various applications such as sterilization blood coagulation and cancer cell treatment. In this paper a pin-to-hole plasma jet suitable for biological applications is investigated, characterized and the possibility and feasibility of cancer cell treatment is evaluated. The characterization includes power consumption via Lissajous method, thermal behavior of plasma using Infra-red camera as a novel method, Optical Emission Spectroscopy (OES) to determine the species that are generated. Treatment of leukemia cancer cells is also implemented and MTT assay is used to evaluate viability. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Atmospheric%20Pressure%20Plasma%20Jet%20%28APPJ%29" title="Atmospheric Pressure Plasma Jet (APPJ)">Atmospheric Pressure Plasma Jet (APPJ)</a>, <a href="https://publications.waset.org/abstracts/search?q=Plasma%20Medicine" title=" Plasma Medicine"> Plasma Medicine</a>, <a href="https://publications.waset.org/abstracts/search?q=Cancer%20cell%20treatment" title=" Cancer cell treatment"> Cancer cell treatment</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=Optical%20Emission" title=" Optical Emission "> Optical Emission </a> </p> <a href="https://publications.waset.org/abstracts/16677/feasibility-of-leukemia-cancer-treatment-k562-by-atmospheric-pressure-plasma-jet" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/16677.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">659</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">78</span> Preparation of Papers - Developing a Leukemia Diagnostic System Based on Hybrid Deep Learning Architectures in Actual Clinical Environments</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Skyler%20Kim">Skyler Kim</a> </p> <p class="card-text"><strong>Abstract:</strong></p> An early diagnosis of leukemia has always been a challenge to doctors and hematologists. On a worldwide basis, it was reported that there were approximately 350,000 new cases in 2012, and diagnosing leukemia was time-consuming and inefficient because of an endemic shortage of flow cytometry equipment in current clinical practice. As the number of medical diagnosis tools increased and a large volume of high-quality data was produced, there was an urgent need for more advanced data analysis methods. One of these methods was the AI approach. This approach has become a major trend in recent years, and several research groups have been working on developing these diagnostic models. However, designing and implementing a leukemia diagnostic system in real clinical environments based on a deep learning approach with larger sets remains complex. Leukemia is a major hematological malignancy that results in mortality and morbidity throughout different ages. We decided to select acute lymphocytic leukemia to develop our diagnostic system since acute lymphocytic leukemia is the most common type of leukemia, accounting for 74% of all children diagnosed with leukemia. The results from this development work can be applied to all other types of leukemia. To develop our model, the Kaggle dataset was used, which consists of 15135 total images, 8491 of these are images of abnormal cells, and 5398 images are normal. In this paper, we design and implement a leukemia diagnostic system in a real clinical environment based on deep learning approaches with larger sets. The proposed diagnostic system has the function of detecting and classifying leukemia. Different from other AI approaches, we explore hybrid architectures to improve the current performance. First, we developed two independent convolutional neural network models: VGG19 and ResNet50. Then, using both VGG19 and ResNet50, we developed a hybrid deep learning architecture employing transfer learning techniques to extract features from each input image. In our approach, fusing the features from specific abstraction layers can be deemed as auxiliary features and lead to further improvement of the classification accuracy. In this approach, features extracted from the lower levels are combined into higher dimension feature maps to help improve the discriminative capability of intermediate features and also overcome the problem of network gradient vanishing or exploding. By comparing VGG19 and ResNet50 and the proposed hybrid model, we concluded that the hybrid model had a significant advantage in accuracy. The detailed results of each model’s performance and their pros and cons will be presented in the conference. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20lymphoblastic%20leukemia" title="acute lymphoblastic leukemia">acute lymphoblastic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=hybrid%20model" title=" hybrid model"> hybrid model</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia%20diagnostic%20system" title=" leukemia diagnostic system"> leukemia diagnostic system</a>, <a href="https://publications.waset.org/abstracts/search?q=machine%20learning" title=" machine learning"> machine learning</a> </p> <a href="https://publications.waset.org/abstracts/145566/preparation-of-papers-developing-a-leukemia-diagnostic-system-based-on-hybrid-deep-learning-architectures-in-actual-clinical-environments" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/145566.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">187</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">77</span> Hematological Malignancies in Children and Parental Occupational Exposure</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=H.%20Kalboussi">H. Kalboussi</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Aloui"> A. Aloui</a>, <a href="https://publications.waset.org/abstracts/search?q=W.%20Boughattas"> W. Boughattas</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Maoua"> M. Maoua</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Brahem"> A. Brahem</a>, <a href="https://publications.waset.org/abstracts/search?q=S.%20Chatti"> S. Chatti</a>, <a href="https://publications.waset.org/abstracts/search?q=O.%20El%20Maalel"> O. El Maalel</a>, <a href="https://publications.waset.org/abstracts/search?q=F.%20Debbabi"> F. Debbabi</a>, <a href="https://publications.waset.org/abstracts/search?q=N.%20%20Mrizak"> N. Mrizak</a>, <a href="https://publications.waset.org/abstracts/search?q=Y.%20Ben%20Youssef"> Y. Ben Youssef</a>, <a href="https://publications.waset.org/abstracts/search?q=A.%20Khlif"> A. Khlif</a>, <a href="https://publications.waset.org/abstracts/search?q=I.%20Bougmiza"> I. Bougmiza</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: In recent decades, the incidence of children's hematological malignancies has been increasing worldwide including Tunisia. Their severity is reflected in the importance of the medical, social and economic impact. This increase remains fully unexplained, and the involvement of genetic, environmental and occupational factors is strongly suspected. Materials and Methods: Our study is a cross-sectional survey of the type case-control conducted in the University Hospital of Farhat Hached of Sousse during the period ranging between 1 July 2011 and 30 June 2012,and which included children with acute leukemia compared to children unharmed by neoplastic disease . Cases and controls were matched by age and gender. Our objective was to: - Describe the socio-occupational characteristics of the parents of children with acute leukemia. - Identify potential occupational factors implicated in the genesis of acute leukemia. Result: The number of acute leukemia cases in the Hematology Service and day hospital of the University Hospital of Farhat Hached during the study period was 66 cases divided into in 40 boys and 26 girls with a sex ratio of 1.53. Our cases and controls were matched by age and gender. The risk of incidence of leukemia in children from smoking fathers was higher (p = 0.02, OR = 2.24, IC = [1.11 - 4.52]). The risk of incidence of leukemia in children from alcoholic fathers was higher with p = 0,009, OR = 3.9; CI = [1.33 - 11.39]. After adjusting different variables, the difference persisted significantly with pa = 0.03 and ORa = 3.5; ICa = [1.09 -11.6]. 25.7 % of cases had a family history of blood disease and neoplasia, whereas no control presented that. The difference was statistically significant (p = 0.006), OR = 1.46, IC = [1.38 - 1.56]. The parental occupational exposures associated to the occurrence of acute leukemia in children were: - Pesticides with a statistically significant difference (p = 0.03), OR = 2.94, IC = [1.06 - 8.13]. This difference persisted after adjustment with different variables pa = 0.01, ORa 3.75; ICa = [1.27 - 11.03]. - Cement without a statistically non-significant difference (p = 0.2). This difference has become significant after adjustment with the different variables pa = 0.03; ORa = 2.67; ICa = [1.06 - 6.7]. Conclusion: Parental exposure to occupational risk factors may play a role in the pathogenesis of acute leukemia in children. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=hematological%20malignancies" title="hematological malignancies">hematological malignancies</a>, <a href="https://publications.waset.org/abstracts/search?q=children" title=" children"> children</a>, <a href="https://publications.waset.org/abstracts/search?q=parents" title=" parents"> parents</a>, <a href="https://publications.waset.org/abstracts/search?q=occupational%20exposure" title=" occupational exposure"> occupational exposure</a> </p> <a href="https://publications.waset.org/abstracts/38548/hematological-malignancies-in-children-and-parental-occupational-exposure" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/38548.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">318</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">76</span> Prognostic Implication of Nras Gene Mutations in Egyptian Adult Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Doaa%20M.%20Elghannam">Doaa M. Elghannam</a>, <a href="https://publications.waset.org/abstracts/search?q=Nashwa%20Khayrat%20Abousamra"> Nashwa Khayrat Abousamra</a>, <a href="https://publications.waset.org/abstracts/search?q=Doaa%20A.%20Shahin"> Doaa A. Shahin</a>, <a href="https://publications.waset.org/abstracts/search?q=Enas%20F.%20Goda"> Enas F. Goda</a>, <a href="https://publications.waset.org/abstracts/search?q=Hanan%20Azzam"> Hanan Azzam</a>, <a href="https://publications.waset.org/abstracts/search?q=Emad%20Azmy"> Emad Azmy</a>, <a href="https://publications.waset.org/abstracts/search?q=Manal%20Salah%20El-Din"> Manal Salah El-Din</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The pathogenesis of acute myeloid leukemia (AML) involves the cooperation of mutations promoting proliferation/survival and those impairing differentiation. Point mutations of the NRAS gene are the most frequent somatic mutations causing aberrant signal-transduction in acute myeloid leukemia (AML). Aim: The present work was conducted to study the frequency and prognostic significance of NRAS gene mutations (NRASmut) in de novo Egyptian adult AML. Material and methods: Bone marrow specimens from 150 patients with de novo acute myeloid leukemia and controls were analyzed by genomic PCR-SSCP at codons 12, 13 (exon 1), and 61 (exon 2) for NRAS mutations. Results: NRAS gene mutations was found in 19/150 (12.7%) AML cases, represented more frequently in the FAB subtype M4eo (P = 0.028), and at codon 12, 13 (14of 19; 73.7%). Patients with NRASmut had a significant lower peripheral marrow blasts (P = 0.004, P=0.03) and non significant improved clinical outcome than patients without the mutation. Complete remission rate was (63.2% vs 56.5%; p=0.46), resistant disease (15.8% vs 23.6%; p=0.51), three years overall survival (44% vs 42%; P = 0.85) and disease free survival (42.1% vs 38.9%, P = 0.74). Multivariate analysis showed that age was the strongest unfavorable factor for overall survival (relative risk [RR], 1.9; P = .002), followed by cytogenetics (P = .004). FAB types, NRAS mutation, and leukocytosis were less important. Conclusions: NRAS gene mutation frequency and spectrum differ between biologically distinct subtypes of AML but do not significantly influence prognosis and clinical outcome. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=NRAS%20Gene" title="NRAS Gene">NRAS Gene</a>, <a href="https://publications.waset.org/abstracts/search?q=egyptian%20adult" title=" egyptian adult"> egyptian adult</a>, <a href="https://publications.waset.org/abstracts/search?q=acute%20myeloid%20leukemia" title=" acute myeloid leukemia"> acute myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=cytogenetics" title=" cytogenetics"> cytogenetics</a> </p> <a href="https://publications.waset.org/abstracts/154231/prognostic-implication-of-nras-gene-mutations-in-egyptian-adult-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/154231.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">99</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">75</span> Study of Demographic, Hematological Profile and Risk Stratification in Chronic Myeloid Leukemia Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rajandeep%20Kaur">Rajandeep Kaur</a>, <a href="https://publications.waset.org/abstracts/search?q=Rajeev%20Gupta"> Rajeev Gupta</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Chronic myeloid leukemia (CML) is the most common leukaemia in India. The annual incidence of chronic myeloid leukemia in India was originally reported to be 0.8 to 2.2 per 1,00,000 population. CML is a clonal disorder that is usually easily diagnosed because the leukemic cells of more than 95% of patients have a distinctive cytogenetic abnormality, the Philadelphia chromosome (Ph1). The approval of tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase activity, has significantly reduced the mortality rate associated with chronic myeloid leukemia (CML) and revolutionized treatment. Material and Methods: 80 diagnosed cases of CML were taken. Investigations were done. Bone marrow and molecular studies were also done and with EUTOS, patients were stratified into low and high-risk groups and then treatment with Imatinib was given to all patients and the molecular response was evaluated at 6 months and 12 months follow up with BCR-ABL by RT-PCR quantitative assay. Results: In the study population, out of 80 patients in the study population, 40 were females and 40 were males, with M: F is 1:1. Out of total 80 patients’ maximum patients (54) were in 31-60 years age group. Our study showed a most common symptom of presentation is abdominal discomfort followed by fever. Out of the total 80 patients, 25 (31.3%) patients had high EUTOS scores and 55 (68.8%) patients had low EUTOS scores. On 6 months follow up 36.3% of patients had Complete Molecular Response, 16.3% of patients had Major Molecular Response and 47.5% of patients had No Molecular Response but on 12 months follow up 71.3% of patients had Complete Molecular Response, 16.25% of patients had Major Molecular Response and 12.5% patients had No Molecular Response. Conclusion: In this study, we found a significant correlation between EUTOS score and Molecular response at 6 months and 12 months follow up after Imatinib therapy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20myeloid%20leukemia" title="chronic myeloid leukemia">chronic myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=European%20treatment%20and%20outcome%20study%20score" title=" European treatment and outcome study score"> European treatment and outcome study score</a>, <a href="https://publications.waset.org/abstracts/search?q=hematological%20response" title=" hematological response"> hematological response</a>, <a href="https://publications.waset.org/abstracts/search?q=molecular%20response" title=" molecular response"> molecular response</a>, <a href="https://publications.waset.org/abstracts/search?q=tyrosine%20kinase%20inhibitor" title=" tyrosine kinase inhibitor"> tyrosine kinase inhibitor</a> </p> <a href="https://publications.waset.org/abstracts/147756/study-of-demographic-hematological-profile-and-risk-stratification-in-chronic-myeloid-leukemia-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/147756.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">101</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">74</span> Central Retinal Venous Occlusion Associated O Bilateral Optic Nerve Infiltration Revealing Relapse Of An Acute Lymphoblastic Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fendouli%20Ines">Fendouli Ines</a>, <a href="https://publications.waset.org/abstracts/search?q=Zaafrane%20Nesrine"> Zaafrane Nesrine</a>, <a href="https://publications.waset.org/abstracts/search?q=Mhamdi%20Hana"> Mhamdi Hana</a>, <a href="https://publications.waset.org/abstracts/search?q=Knani%20Leila"> Knani Leila</a>, <a href="https://publications.waset.org/abstracts/search?q=Ghorbel%20Mohamed"> Ghorbel Mohamed</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introduction: Ocular infiltration of leukemia can involve orbit, uveal tract, retina and optic nerve. It may result from direct ocular infiltration by leukemic cells or indirect ocular involvement resulting from secondary hematologic changes, opportunistic infections and complications of various modalities of therapy. We here in report a case of central venous retinal occlusion associated to optic nerve infiltration as presenting signs of a relapse of acute lymphoblastic leukemia. Case Report: A twelve-year-old male -patient of acute B lymphoblastic leukemia presented with headaches and bilateral blurred vision in the left ee. Ophthalmic examination showed a visual acuity reduced to counting fingers in the right eye and no light perception in the left eye. Funduscopy revealed a voluminous disc edema surrounded by retinal haemorrhages in the right eye, and venous tortusities, papillary edema, and hemorrages suggesting central retinal venous occlusion in the LE. Swept source optical coherence tomography revealed a serous retinal detachment in the RE and .hyperreflective inner layers with macular edema in the left eye. Cerebro-orbital MRI showed bilateral thickened left optic nerve. There were no radiological signs of true papillary edema due to intracranial hypertension secondary to central nervous system involvement. Myelogram and lumbar punction demonstrated blast infiltration and confirmed ocular relapse of the leukemia. Conclusion: Ocular involvement lymphoblastic acute leukemias decreased since the introduction of a systematic prophylactic treatment of central nervous system. Periodic ophthalmic examination is necessary to allow early diagnosis and treatment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20leukemia" title="acute leukemia">acute leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=optic%20nerve" title=" optic nerve"> optic nerve</a>, <a href="https://publications.waset.org/abstracts/search?q=infiltration" title=" infiltration"> infiltration</a>, <a href="https://publications.waset.org/abstracts/search?q=relapse" title=" relapse"> relapse</a> </p> <a href="https://publications.waset.org/abstracts/167221/central-retinal-venous-occlusion-associated-o-bilateral-optic-nerve-infiltration-revealing-relapse-of-an-acute-lymphoblastic-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/167221.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">90</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">73</span> Global Stability Analysis of a Coupled Model for Healthy and Cancerous Cells Dynamics in Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Abdelhafid%20Zenati">Abdelhafid Zenati</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Tadjine"> Mohamed Tadjine</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The mathematical formulation of biomedical problems is an important phase to understand and predict the dynamic of the controlled population. In this paper we perform a stability analysis of a coupled model for healthy and cancerous cells dynamics in Acute Myeloid Leukemia, this represents our first aim. Second, we illustrate the effect of the interconnection between healthy and cancer cells. The PDE-based model is transformed to a nonlinear distributed state space model (delay system). For an equilibrium point of interest, necessary and sufficient conditions of global asymptotic stability are given. Thus, we came up to give necessary and sufficient conditions of global asymptotic stability of the origin and the healthy situation and control of the dynamics of normal hematopoietic stem cells and cancerous during myelode Acute leukemia. Simulation studies are given to illustrate the developed results. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=distributed%20delay" title="distributed delay">distributed delay</a>, <a href="https://publications.waset.org/abstracts/search?q=global%20stability" title=" global stability"> global stability</a>, <a href="https://publications.waset.org/abstracts/search?q=modelling" title=" modelling"> modelling</a>, <a href="https://publications.waset.org/abstracts/search?q=nonlinear%20models" title=" nonlinear models"> nonlinear models</a>, <a href="https://publications.waset.org/abstracts/search?q=PDE" title=" PDE"> PDE</a>, <a href="https://publications.waset.org/abstracts/search?q=state%20space" title=" state space"> state space</a> </p> <a href="https://publications.waset.org/abstracts/58988/global-stability-analysis-of-a-coupled-model-for-healthy-and-cancerous-cells-dynamics-in-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/58988.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">252</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">72</span> The Use of Geographic Information System and Spatial Statistic for Analyzing Leukemia in Kuwait for the Period of 2006-2012</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Muhammad%20G.%20Almatar">Muhammad G. Almatar</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammad%20A.%20Alnasrallah"> Mohammad A. Alnasrallah</a> </p> <p class="card-text"><strong>Abstract:</strong></p> This research focuses on the study of three main issues: 1) The temporal analysis of leukemia for a period of six years (2006-2012), 2) spatial analysis by investigating this phenomenon in the Kuwaiti society spatially in the residential areas within the six governorates, 3) the use of Geographic Information System technology in investigating the hypothesis of the research and its variables using the linear regression, to show the pattern of linear relationship. The study depends on utilizing the map to understand the distribution of blood cancer in Kuwait. Several geodatabases were created for the number of patients and air pollution. Spatial interpolation models were used to generate layers of air pollution in the study area. These geodatabases were tested over the past six years to reach the conclusion: Is there a relationship with significant significance between the two main variables of the study: blood cancer and air pollution? This study is the first to our best knowledge. As far as the researchers know, the distribution of this disease has not been studied geographically at the level of regions in Kuwait within six years and in specific areas as described above. This study investigates the concentration of this type of disease. The study found that there is no relationship of significant value between the two variables studied, and this may be due to the nature of the disease, which are often hereditary. On the other hand, this study has reached a number of suggestions and recommendations that may be useful to decision-makers and interested in the study of leukemia in Kuwait by focusing on the study of genetic diseases, which may be a cause of leukemia rather than air pollution. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kuwait" title="Kuwait">Kuwait</a>, <a href="https://publications.waset.org/abstracts/search?q=GIS" title=" GIS"> GIS</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=geography" title=" geography"> geography</a> </p> <a href="https://publications.waset.org/abstracts/110610/the-use-of-geographic-information-system-and-spatial-statistic-for-analyzing-leukemia-in-kuwait-for-the-period-of-2006-2012" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/110610.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">114</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">71</span> Predication Model for Leukemia Diseases Based on Data Mining Classification Algorithms with Best Accuracy</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Fahd%20Sabry%20Esmail">Fahd Sabry Esmail</a>, <a href="https://publications.waset.org/abstracts/search?q=M.%20Badr%20Senousy"> M. Badr Senousy</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohamed%20Ragaie"> Mohamed Ragaie</a> </p> <p class="card-text"><strong>Abstract:</strong></p> In recent years, there has been an explosion in the rate of using technology that help discovering the diseases. For example, DNA microarrays allow us for the first time to obtain a "global" view of the cell. It has great potential to provide accurate medical diagnosis, to help in finding the right treatment and cure for many diseases. Various classification algorithms can be applied on such micro-array datasets to devise methods that can predict the occurrence of Leukemia disease. In this study, we compared the classification accuracy and response time among eleven decision tree methods and six rule classifier methods using five performance criteria. The experiment results show that the performance of Random Tree is producing better result. Also it takes lowest time to build model in tree classifier. The classification rules algorithms such as nearest- neighbor-like algorithm (NNge) is the best algorithm due to the high accuracy and it takes lowest time to build model in classification. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=data%20mining" title="data mining">data mining</a>, <a href="https://publications.waset.org/abstracts/search?q=classification%20techniques" title=" classification techniques"> classification techniques</a>, <a href="https://publications.waset.org/abstracts/search?q=decision%20tree" title=" decision tree"> decision tree</a>, <a href="https://publications.waset.org/abstracts/search?q=classification%20rule" title=" classification rule"> classification rule</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia%20diseases" title=" leukemia diseases"> leukemia diseases</a>, <a href="https://publications.waset.org/abstracts/search?q=microarray%20data" title=" microarray data"> microarray data</a> </p> <a href="https://publications.waset.org/abstracts/44376/predication-model-for-leukemia-diseases-based-on-data-mining-classification-algorithms-with-best-accuracy" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/44376.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">320</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">70</span> The Molecular Rationale for Steroid Based Therapy of Leukemia: Diagnostic and Therapeutic Implications </h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Eitan%20Yefenof">Eitan Yefenof</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Glucocorticoid (GC) hormones, e.g. Dexamethasone and Prednisone, are widely used in the therapy of leukemia and lymphoma owing to their apoptogenic effect on lymphoid cells. However, the emergence of GC resistant cells during therapy is a major cause for treatment failure, urging the need for novel strategies that maintain leukemia sensitivity to the pro-apoptotic activity of GCs. GCs act by binding to the GC receptor (GR), which, in its inactive state, is sequestered in the cytosol by a multi-subunit complex of heat shock proteins. Upon ligand binding, the complex dissociates, allowing GR activation and translocation to the nucleus, where it regulates transcription of multiple genes. We demonstrated that in addition to gene expression, GR also regulates microRNA (miR) expression. Deep-sequencing analysis revealed 14 miRs that are regulated in GC-sensitive but resistant leukemias upon treatment with GC. GC up-regulates miR-103, miR-15~16 and miR-30e/d, while down-regulates miR-17, mir-18a, miR-19a, miR-19b, miR-20a and miR-92a (members of the miR-17∼92a multi-cistron). Upon transfection, miR-103 confers GC apoptotic sensitivity to otherwise GC-resistant cell. Furthermore, knocking down miR-103 expression reduces the GC apoptotic response of sensitive cells. miR-103 abrogates c-Myc expression, an oncogenic transcription factor which is deregulated in many cancers. In addition, miR-103 up-regulates Bim, a pro-apoptotic protein crucial for GC-induced death. Activated glycogen synthase kinase 3 (GSK3) is also crucial for GC-induced apoptosis. GSK3 is active in GC-sensitive but not in GC-resistant cells. We found that GSK3 associates with the GR multi-subunit complex. Upon GC exposure, it dissociates from the GR and interacts with Bim to enable activation of the mitochondrial apoptosis pathway. miR-103 mediated c-Myc ablation is followed by down-regulation of the multi-cistron miR-17~92a, in particular miR-18a and miR-20a. miR-18a targets GR for degradation whereas miR-20a targets Bim degradation. Hence, miR-103 acts, in concert with Bim and GR, as a "tumor suppressor" that leads to reduced proliferation, cell-cycle arrest and cell death. We suggest that miR-103 can provide a diagnostic tool that predicts the sensitivity of leukemia to GC based therapy. Furthermore, exosomal delivery of miR-103 or up-regulation of the endogenous miR-103 could confer apoptotic sensitivity to resistant cells at the outset, thus becoming a useful therapeutic tool combined with GCs. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=apoptosis" title="apoptosis">apoptosis</a>, <a href="https://publications.waset.org/abstracts/search?q=leukemia" title=" leukemia"> leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=micro-RNA" title=" micro-RNA"> micro-RNA</a>, <a href="https://publications.waset.org/abstracts/search?q=steroids" title=" steroids"> steroids</a> </p> <a href="https://publications.waset.org/abstracts/39496/the-molecular-rationale-for-steroid-based-therapy-of-leukemia-diagnostic-and-therapeutic-implications" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/39496.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">246</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">69</span> Prevalence of Methylenetetrahydrofolate Reductase A1298C Variant in Tunisian Childhood Acute Lymphoblastic Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rim%20Frikha">Rim Frikha</a>, <a href="https://publications.waset.org/abstracts/search?q=Maha%20Ben%20Jema"> Maha Ben Jema</a>, <a href="https://publications.waset.org/abstracts/search?q=Moez%20Elloumi"> Moez Elloumi</a>, <a href="https://publications.waset.org/abstracts/search?q=Tarek%20Rebai"> Tarek Rebai</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Acute lymphoblastic leukemia (ALL); a common blood cancer characterized by the interaction between genetic and environmental factors. Methylenetetrahydrofolate reductase (MTHFR) is an essential folate metabolic enzyme in the processes of DNA synthesis and methylation. A common functional variant of the MTHFR gene, the A1298C, which induces disturbances in folate metabolism, may affect susceptibility to ALL. Objective: The present study aimed to assess the prevalence of MTHFR polymorphism A1298 > C in Tunisian children with ALL. Materials and Methods: A total of 28 Tunisian ALL children were enrolled in this study. Genomic DNA was extracted from whole venous blood collected in ethylenediaminetetraacetic acid (EDTA). Genotyping was carried out with restriction fragment length polymorphism (RFLP) using MboII restriction enzyme. Genotype distribution and allele frequency of MTHFR A1298C was calculated in ALL patients. Results: The A1298C variant of MTHFR was found in 11(19.6%) heterozygous and one homozygous patient (3.5%). Conclusions: This result highlights that A1298C polymorphism of MTHFR is common in Tunisian childhood ALL and suggests that this variant may have a potential role in leukemogenesis. Genotyping of large samples and different ethnicities are required to validate these findings. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=methylenetetrahydrofolate%20reductase" title="methylenetetrahydrofolate reductase">methylenetetrahydrofolate reductase</a>, <a href="https://publications.waset.org/abstracts/search?q=acute%20lymphoblastic%20leukemia" title=" acute lymphoblastic leukemia"> acute lymphoblastic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=A1298C%20variant" title=" A1298C variant"> A1298C variant</a>, <a href="https://publications.waset.org/abstracts/search?q=prevalence" title=" prevalence"> prevalence</a> </p> <a href="https://publications.waset.org/abstracts/121322/prevalence-of-methylenetetrahydrofolate-reductase-a1298c-variant-in-tunisian-childhood-acute-lymphoblastic-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/121322.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">135</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">68</span> Altered TP53 Mutations in de Novo Acute Myeloid Leukemia Patients in Iran</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Naser%20Shagerdi%20Esmaeli">Naser Shagerdi Esmaeli</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohsen%20Hamidpour"> Mohsen Hamidpour</a>, <a href="https://publications.waset.org/abstracts/search?q=Parisa%20Hasankhani%20Tehrani"> Parisa Hasankhani Tehrani</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: The TP53 mutation is frequently detected in acute myeloid leukemia (AML) patients with complex karyotype (CK), but the stability of this mutation during the clinical course remains unclear. Material and Methods: In this study, TP53 mutations were identified in 7% of 500 patients with de novo AML and 58.8% of patients with CK in Tabriz, Iran. TP53 mutations were closely associated with older age, lower white blood cell (WBC) and platelet counts, FAB M6 subtype, unfavorable-risk cytogenetics, and CK, but negatively associated with NPM1 mutation, FLT3/ITD and DNMT3A mutation. Result: Multivariate analysis demonstrated that TP53 mutation was an independent poor prognostic factor for overall survival and disease-free survival among the total cohort and the subgroup of patients with CK. A scoring system incorporating TP53 mutation and nine other prognostic factors, including age, WBC counts, cytogenetics, and gene mutations, into survival analysis proved to be very useful to stratify AML patients. Sequential study of 420 samples showed that TP53 mutations were stable during AML evolution, whereas the mutation was acquired only in 1 of the 126 TP53 wild-type patients when therapy-related AML originated from different clone emerged. Conclusion: In conclusion, TP53 mutations are associated with distinct clinic-biological features and poor prognosis in de novo AML patients and are rather stable during disease progression. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20myloblastic%20leukemia" title="acute myloblastic leukemia">acute myloblastic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=TP53" title=" TP53"> TP53</a>, <a href="https://publications.waset.org/abstracts/search?q=FLT3%2FITD" title=" FLT3/ITD"> FLT3/ITD</a>, <a href="https://publications.waset.org/abstracts/search?q=Iran" title=" Iran"> Iran</a> </p> <a href="https://publications.waset.org/abstracts/158096/altered-tp53-mutations-in-de-novo-acute-myeloid-leukemia-patients-in-iran" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/158096.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">107</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">67</span> Epidemiological Survey of Feline Leukemia Virus in Domestic Cats on Tsushima Island, Japan: Tsushima Leopard Cats Are at Risk</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Isaac%20Makundi">Isaac Makundi</a>, <a href="https://publications.waset.org/abstracts/search?q=Kazuo%20Nishigaki"> Kazuo Nishigaki</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The Tsushima leopard cat (TLC) Prionailurus bengalensis euptilurus, designated a National Natural Monument of Japan, inhabits Tsushima Island, Nagasaki Prefecture, Japan. TLC is considered a subspecies of P. bengalensis, and lives only on Tsushima Island. TLCs are threatened by various infectious diseases. Feline leukemia virus (FeLV) causes a serious infectious disease with a poor prognosis in cats. Therefore, the transmission of FeLV from Tsushima domestic cats (TDCs) to TLCs may threaten the TLC population. We investigated the FeLV infection status of both TDCs and TLCs on Tsushima Island by screening blood samples for FeLV p27 antigen and using PCR to amplify the full-length FeLV env gene. The prevalence of FeLV was 6.4% in TDCs and 0% in TLCs. We also demonstrated that the virus can replicate in the cells of TLCs, suggesting its potential cross-species transmission. The viruses in TDCs were classified as genotype I/clade 3, which is prevalent on a nearby island, based on previous studies of FeLV genotypes and FeLV epidemiology. The FeLV viruses identified on Tsushima Island can be further divided into two lineages within genotype I/clade 3, which are geographically separated in Kamijima and Shimojima, indicating that FeLV may have been transmitted to Tsushima Island at least twice. Monitoring FeLV infection in the TDC and TLC populations is highly recommended as part of the TLC surveillance and management strategy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=epidemiology" title="epidemiology">epidemiology</a>, <a href="https://publications.waset.org/abstracts/search?q=Feline%20leukemia%20virus" title=" Feline leukemia virus"> Feline leukemia virus</a>, <a href="https://publications.waset.org/abstracts/search?q=Tsushima%20Island" title=" Tsushima Island"> Tsushima Island</a>, <a href="https://publications.waset.org/abstracts/search?q=wildlife%20management" title=" wildlife management"> wildlife management</a> </p> <a href="https://publications.waset.org/abstracts/58000/epidemiological-survey-of-feline-leukemia-virus-in-domestic-cats-on-tsushima-island-japan-tsushima-leopard-cats-are-at-risk" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/58000.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">206</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">66</span> Antigen-Presenting Cell Characteristics of Human γδ T Lymphocytes in Chronic Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Piamsiri%20Sawaisorn">Piamsiri Sawaisorn</a>, <a href="https://publications.waset.org/abstracts/search?q=Tienrat%20%20Tangchaikeeree"> Tienrat Tangchaikeeree</a>, <a href="https://publications.waset.org/abstracts/search?q=Waraporn%20Chan-On"> Waraporn Chan-On</a>, <a href="https://publications.waset.org/abstracts/search?q=Chaniya%20Leepiyasakulchai"> Chaniya Leepiyasakulchai</a>, <a href="https://publications.waset.org/abstracts/search?q=Rachanee%20Udomsangpetch"> Rachanee Udomsangpetch</a>, <a href="https://publications.waset.org/abstracts/search?q=Suradej%20Hongeng"> Suradej Hongeng</a>, <a href="https://publications.waset.org/abstracts/search?q=Kulachart%20Jangpatarapongsa"> Kulachart Jangpatarapongsa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Human Vγ9Vδ2 T lymphocytes are regarded as promising effector cells for cancer immunotherapy since they have the ability to eliminate several tumor cells through non-peptide antigen recognition and non-major histocompatibility complex (MHC) restriction. An issue of recent interest is the capability to activate γδ T cells by use of a group of drugs, such as pamidronate, that cause accumulation of phosphoantigen which is recognized by γδ T cell receptors. Moreover, their antigen presenting cell-like phenotype and function have been confirmed in many clinical trials. In this study, Vγ9Vδ2 T cells derived from normal peripheral blood mononuclear cells were activated with pamidronate and the expanded Vγ9Vδ2 T cells can recognize and kill chronic myeloid leukemia (CML) cells treated with pamidronate through their cytotoxic activity. To support the strong role played by Vγ9Vδ2 T cells against cancer, we provide the evidence that Vγ9Vδ2 T cells activated with CML cell lysate antigen can efficiently express antigen presenting cell (APC) phenotype and function. In conclusion, pamidronate can be used in intentional activation of human Vγ9Vδ2 T cells and can increase the susceptibility of CML cells to cytotoxicity of Vγ9Vδ2 T cells. The activated Vγ9Vδ2 T cells by cancer cells lysate can show their APC characteristics, and so greatly increase the interest in exploring their therapeutic potential in hematologic malignancy. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=%CE%B3%CE%B4%20T%20lymphocytes" title="γδ T lymphocytes">γδ T lymphocytes</a>, <a href="https://publications.waset.org/abstracts/search?q=antigen-presenting%20cells" title=" antigen-presenting cells"> antigen-presenting cells</a>, <a href="https://publications.waset.org/abstracts/search?q=chronic%20myeloid%20leukemia" title=" chronic myeloid leukemia"> chronic myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer" title=" cancer"> cancer</a>, <a href="https://publications.waset.org/abstracts/search?q=immunotherapy" title=" immunotherapy"> immunotherapy</a> </p> <a href="https://publications.waset.org/abstracts/103440/antigen-presenting-cell-characteristics-of-human-ghd-t-lymphocytes-in-chronic-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/103440.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">186</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">65</span> PYURF and ZED9 Have a Prominent Role in Association with Molecular Pathways in Bortezomib in Myeloma Cells in Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Atena%20Sadat%20Hosseini">Atena Sadat Hosseini</a>, <a href="https://publications.waset.org/abstracts/search?q=Mohammadhossein%20Habibi"> Mohammadhossein Habibi</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Acute myeloid leukemia (AML) is the most typically diagnosed leukemia. In older adults, AML imposes a dismal outcome. AML originates with a dominant mutation, then adds collaborative, transformative mutations leading to myeloid transformation and clinical/biological heterogeneity. Several chemotherapeutic drugs are used for this cancer. These drugs are naturally associated with several side effects, and finding a more accurate molecular mechanism of these drugs can have a significant impact on the selection and better candidate of drugs for treatment. In this study, we evaluated bortezomibin myeloma cells using bioinformatics analysis and evaluation of RNA-Seq data. Then investigated the molecular pathways proteins- proteins interactions associated with this chemotherapy drug. A total of 658upregulated genes and 548 downregulated genes were sorted.AUF1 (hnRNP D0) binds and destabilizes mRNA, degradation of GLI2 by the proteasome, the role of GTSE1 in G2/M progression after G2 checkpoint, TCF dependent signaling in response to WNT demonstrated in upregulated genes. Besides insulin resistance, AKT phosphorylates targets in the nucleus, cytosine methylation, Longevity regulating pathway, and Signal Transduction of S1P Receptor were related to low expression genes. With respect to this results, HIST2H2AA3, RP11-96O20.4, ZED9, PRDX1, and DOK2, according to node degrees and betweenness elements candidates from upregulated genes. in the opposite side, PYURF, NRSN1, FGF23, UPK3BL, and STAG3 were a prominent role in downregulated genes. Sum up, Using in silico analysis in the present study, we conducted a precise study ofbortezomib molecular mechanisms in myeloma cells. so that we could take further evaluation to discovermolecular cancer therapy. Naturally, more additional experimental and clinical procedures are needed in this survey. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=myeloma%20cells" title="myeloma cells">myeloma cells</a>, <a href="https://publications.waset.org/abstracts/search?q=acute%20myeloid%20leukemia" title=" acute myeloid leukemia"> acute myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=bioinformatics%20analysis" title=" bioinformatics analysis"> bioinformatics analysis</a>, <a href="https://publications.waset.org/abstracts/search?q=bortezomib" title=" bortezomib"> bortezomib</a> </p> <a href="https://publications.waset.org/abstracts/149978/pyurf-and-zed9-have-a-prominent-role-in-association-with-molecular-pathways-in-bortezomib-in-myeloma-cells-in-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/149978.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">93</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">64</span> Successful Cesarean Delivery with Veno-Venous Extracorporeal Membrane Oxygenation Support in a Pregnant Woman with Severe Acute Respiratory Distress Syndrome and Heart Failure Complicated by a Rare Condition of Pre-B Cell Acute Lymphoblastic Leukemia in P</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kristel%20Dame%20Ba%C3%B1ez%20Sumagaysay">Kristel Dame Bañez Sumagaysay</a>, <a href="https://publications.waset.org/abstracts/search?q=Marie%20Victoria%20Cruz-javier"> Marie Victoria Cruz-javier</a> </p> <p class="card-text"><strong>Abstract:</strong></p> The current subject is a case of a 21 year-old woman at 29 1/7 weeks of gestation with Pre-B cell Acute Lymphoblastic Leukemia who was admitted to the coronary care unit (CCU) of the St. Luke’s Medical Center-Global City for Severe Acute Respiratory Distress Syndrome (ARDS) secondary to hospital-acquired pneumonia secondary to pneumocystis jiroveci; central line-associated bloodstream infection (E. aerogenes). She presented with chronic hypoxemia caused by Pulmonary edema, probably secondary to heart failure secondary to cardiomyopathy chemotherapy-induced. Due to worsening feto-maternal status, extracorporeal membrane oxygenation (ECMO) for respiratory support was instituted, and an elective cesarean section was done due to multiple maternal factors and deteriorating health status under total intravenous anesthesia assisted by veno-venous extracorporeal membrane oxygenation. She delivered a live preterm newborn male, APGAR Score: 1, 0, 0, birth weight 985 grams, birth length: 40.5cm, small for gestational age. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=extracorporeal%20membrane%20oxygenation" title="extracorporeal membrane oxygenation">extracorporeal membrane oxygenation</a>, <a href="https://publications.waset.org/abstracts/search?q=pre-b%20cell%20acute%20lymphoblastic%20leukemia" title=" pre-b cell acute lymphoblastic leukemia"> pre-b cell acute lymphoblastic leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=severe%20acute%20respiratory%20distress%20syndrome" title=" severe acute respiratory distress syndrome"> severe acute respiratory distress syndrome</a>, <a href="https://publications.waset.org/abstracts/search?q=ethical%20dilemmas" title=" ethical dilemmas"> ethical dilemmas</a> </p> <a href="https://publications.waset.org/abstracts/168204/successful-cesarean-delivery-with-veno-venous-extracorporeal-membrane-oxygenation-support-in-a-pregnant-woman-with-severe-acute-respiratory-distress-syndrome-and-heart-failure-complicated-by-a-rare-condition-of-pre-b-cell-acute-lymphoblastic-leukemia-in-p" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/168204.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">73</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">63</span> Indoleamine 2,3 Dioxygenase and Regulatory T Cells in Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Iman%20M.%20Mansour">Iman M. Mansour</a>, <a href="https://publications.waset.org/abstracts/search?q=Rania%20A.%20Zayed"> Rania A. Zayed</a>, <a href="https://publications.waset.org/abstracts/search?q=Fadwa%20S.%20Abdel-Azim"> Fadwa S. Abdel-Azim</a>, <a href="https://publications.waset.org/abstracts/search?q=Lamyaa%20H.%20Abdel-Latif"> Lamyaa H. Abdel-Latif</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background and Objectives: The microenvironment of acute myeloid leukemia (AML) is suppressive for immune cells. Regulatory T cells (Tregs) have been recognized to play a role in helping leukemic cells to evade immunesurveillance. The mesenchymal stem cells (MSCs) are essential contributors in immunomodulation of the microenvironment as they can promote differentiation of Tregs via the indoleamine 2,3-dioxygenase (IDO) pathway. The aim of the present work was to evaluate the expression of IDO in bone marrow derived MSCs and to study its correlation to percentage of Tregs. Methods: 37 adult bone marrow samples were cultured in appropriate culture medium to isolate MSCs. Successful harvest of MSCs was determined by plastic adherence, morphology and positive expression of CD271 and CD105; negative expression of CD34 and CD45 using flowcytometry. MSCs were examined for IDO expression by immunocytochemistry using anti-IDO monoclonal antibody. CD4+ CD25+ cells (Tregs) were measured in bone marrow samples by flowcytometry. Results: MSCs were successfully isolated from 20 of the 37 bone marrow samples cultured. MSCs showed higher expression of IDO and Tregs percentage was higher in AML patients compared to control subjects (p=0.002 and p<0.001 respectively). A positive correlation was found between IDO expression and Tregs percentage (p value=0.012, r=0.5). Conclusion: In this study, we revealed an association between high IDO expression in MSCs and elevated levels of Tregs which has an important role in the pathogenesis of AML, providing immunosuppressive microenvironment. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20myeloid%20leukemia" title="acute myeloid leukemia">acute myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=indoleamine%202" title=" indoleamine 2"> indoleamine 2</a>, <a href="https://publications.waset.org/abstracts/search?q=3-dioxygenase" title="3-dioxygenase">3-dioxygenase</a>, <a href="https://publications.waset.org/abstracts/search?q=mesenchymal%20stem%20cells" title=" mesenchymal stem cells"> mesenchymal stem cells</a>, <a href="https://publications.waset.org/abstracts/search?q=T%20regulatory%20cells" title=" T regulatory cells"> T regulatory cells</a> </p> <a href="https://publications.waset.org/abstracts/24445/indoleamine-23-dioxygenase-and-regulatory-t-cells-in-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/24445.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">359</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">62</span> Preparation of Polymer-Stabilized Magnetic Iron Oxide as Selective Drug Nanocarriers to Human Acute Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kheireddine%20El-Boubbou">Kheireddine El-Boubbou</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Drug delivery to target human acute myeloid leukemia (AML) using a nanoparticulate chemotherapeutic formulation that can deliver drugs selectively to AML cancer is hugely needed. In this work, we report the development of a nanoformulation made of polymeric-stabilized multifunctional magnetic iron oxide nanoparticles (PMNP) loaded with the anticancer drug Doxorubicin (Dox) as a promising drug carrier to treat AML. Dox@PMNP conjugates simultaneously exhibited high drug content, maximized fluorescence, and excellent release properties. Nanoparticulate uptake and cell death following addition of Dox@PMNPs were then evaluated in different types of human AML target cells, as well as on normal human cells. While the unloaded MNPs were not toxic to any of the cells, Dox@PMNPs were found to be highly toxic to the different AML cell lines, albeit at different inhibitory concentrations (IC<sub>50</sub> values), but showed very little toxicity towards the normal cells. In comparison, free Dox showed significant potency concurrently to all the cell lines, suggesting huge potentials for the use of Dox@PMNPs as selective AML anticancer cargos. Live confocal imaging, fluorescence and electron microscopy confirmed that Dox is indeed delivered to the nucleus in relatively short periods of time, causing apoptotic cell death. Importantly, this targeted payload may potentially enhance the effectiveness of the drug in AML patients and may further allow physicians to image leukemic cells exposed to Dox@PMNPs using MRI. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=magnetic%20nanoparticles" title="magnetic nanoparticles">magnetic nanoparticles</a>, <a href="https://publications.waset.org/abstracts/search?q=drug%20delivery" title=" drug delivery"> drug delivery</a>, <a href="https://publications.waset.org/abstracts/search?q=acute%20myeloid%20leukemia" title=" acute myeloid leukemia"> acute myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=iron%20oxide" title=" iron oxide"> iron oxide</a>, <a href="https://publications.waset.org/abstracts/search?q=cancer%20nanotherapy" title=" cancer nanotherapy"> cancer nanotherapy</a> </p> <a href="https://publications.waset.org/abstracts/65856/preparation-of-polymer-stabilized-magnetic-iron-oxide-as-selective-drug-nanocarriers-to-human-acute-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/65856.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">229</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">61</span> Frequency of BCR-ABL Fusion Transcript Types with Chronic Myeloid Leukemia by Multiplex Polymerase Chain Reaction in Srinagarind Hospital, Khon Kaen Thailand</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Kanokon%20Chaicom">Kanokon Chaicom</a>, <a href="https://publications.waset.org/abstracts/search?q=Chitima%20Sirijerachai"> Chitima Sirijerachai</a>, <a href="https://publications.waset.org/abstracts/search?q=Kanchana%20%20Chansung"> Kanchana Chansung</a>, <a href="https://publications.waset.org/abstracts/search?q=Pinsuda%20Klangsang"> Pinsuda Klangsang</a>, <a href="https://publications.waset.org/abstracts/search?q=Boonpeng%20Palaeng"> Boonpeng Palaeng</a>, <a href="https://publications.waset.org/abstracts/search?q=Prajuab%20Chaimanee"> Prajuab Chaimanee</a>, <a href="https://publications.waset.org/abstracts/search?q=Pimjai%20Ananta"> Pimjai Ananta</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Chronic myeloid leukemia (CML) is characterized by the consistent involvement of the Philadelphia chromosome (Ph), which is derived from a reciprocal translocation between chromosome 9 and 22, the main product of the t(9;22) (q34;q11) translocation, is found in the leukemic clone of at least 95% of CML patients. There are two major forms of the BCR/ABL fusion gene, involving ABL exon 2, but including different exons of BCR gene. The transcripts b2a2 (e13a2) or b3a2 (e14a2) code for a p210 protein. Another fusion gene leads to the expression of an e1a2 transcript, which codes for a p190 protein. Other less common fusion genes are b3a3 or b2a3, which codes for a p203 protein and e19a2 (c3a2) transcript, which codes for a p230 protein. Its frequency varies in different populations. In this study, we aimed to report the frequency of BCR-ABL fusion transcript types with CML by multiplex PCR (polymerase chain reaction) in Srinagarind Hospital, Khon Kaen, Thailand. Multiplex PCR for BCR-ABL was performed on 58 patients, to detect different types of BCR-ABL transcripts of the t (9; 22). All patients examined were positive for some type of BCR/ABL rearrangement. The majority of the patients (93.10%) expressed one of the p210 BCR-ABL transcripts, b3a2 and b2a2 transcripts were detected in 53.45% and 39.65% respectively. The expression of an e1a2 transcript showed 3.75%. Co-expression of p210/p230 was detected in 3.45%. Co-expression of p210/p190 was not detected. Multiplex PCR is useful, saves time and reliable in the detection of BCR-ABL transcript types. The frequency of one or other rearrangement in CML varies in different population. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20myeloid%20leukemia" title="chronic myeloid leukemia">chronic myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=BCR-ABL%20fusion%20transcript%20types" title=" BCR-ABL fusion transcript types"> BCR-ABL fusion transcript types</a>, <a href="https://publications.waset.org/abstracts/search?q=multiplex%20PCR" title=" multiplex PCR"> multiplex PCR</a>, <a href="https://publications.waset.org/abstracts/search?q=frequency%20of%20BCR-ABL%20fusion" title=" frequency of BCR-ABL fusion"> frequency of BCR-ABL fusion</a> </p> <a href="https://publications.waset.org/abstracts/91777/frequency-of-bcr-abl-fusion-transcript-types-with-chronic-myeloid-leukemia-by-multiplex-polymerase-chain-reaction-in-srinagarind-hospital-khon-kaen-thailand" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/91777.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">244</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">60</span> Prayer Therapy in a Case of Acute Myeloid Leukemia: The Good, the Bad and the Ugly</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Rubai%20M.%20Ochieng">Rubai M. Ochieng</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Cancer, which accounts for 7 percent of deaths per year in Kenya, is the third highest cause of death after infectious and cardiovascular diseases. Awareness Campaigns have tended to focus on leading cancers including breast and cervical for women as well as prostrate and Esophageal for men. Consequently, less common cancers such as Acute Myeloid Leukemia (AML) are rarely properly understood by the general population and a section of the medical fraternity. Diagnoses of AML in patients who may not have heard about it sometimes results in shock, denial and confusion not just to the diagnosed, but also to their family and friends. The diagnosed and caregivers are bound to receive a lot of contradicting information about prognosis, care and treatment of AML. This information, which often comes from diverse sources including doctors, friends, internet and social media platforms, causes further confusion and panic. The situation is handled differently by different people. Religious people sometimes resort to prayer. This paper, written from the perspective of a care giver, is based on data collected from a case of Acute Myeloid Leukemia diagnosed in a 32 year old male who lost his life within six weeks of diagnosis. The sample constitutes of 16 people who participated in prayers. Out of this total, 5 were males including the diagnosed and 11 were females. All the 16 were Christians of protestant orientation including Anglicans, Quakers and Church of God members. Data was collected by the researcher herself through participant of observation. Findings discuss how the 16 participants prayed individually at different times, together in an overnight prayer meeting and every morning through a group social media platform. They shared songs and words of encouragement from the bible. The group prayed for healing, peace and strength to the diagnosed and family, financial breakthrough and doctors’ work and decisions, among other challenges that came with the situation. The paper reveals the immense benefits of prayer to the diagnosed and his close relatives and friends. They include acceptance of the condition and a positive attitude in handling the challenges that arose from the disease and treatment processes. The challenges arising from the prayer approach of handling the situation are also discussed. The paper concludes that prayer as therapy goes a long way in cancer management. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=acute%20myeloid%20leukemia" title="acute myeloid leukemia">acute myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=Kenya" title=" Kenya"> Kenya</a>, <a href="https://publications.waset.org/abstracts/search?q=participant%20observation" title=" participant observation"> participant observation</a>, <a href="https://publications.waset.org/abstracts/search?q=prayer" title=" prayer"> prayer</a> </p> <a href="https://publications.waset.org/abstracts/80746/prayer-therapy-in-a-case-of-acute-myeloid-leukemia-the-good-the-bad-and-the-ugly" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/80746.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">162</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">59</span> The Predictive Value of Micro Rna 451 on the Outcome of Imatinib Treatment in Chronic Myeloid Leukemia Patients</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Nehal%20Adel%20Khalil">Nehal Adel Khalil</a>, <a href="https://publications.waset.org/abstracts/search?q=Amel%20Foad%20Ketat"> Amel Foad Ketat</a>, <a href="https://publications.waset.org/abstracts/search?q=Fairouz%20Elsayed%20Mohamed%20Ali"> Fairouz Elsayed Mohamed Ali</a>, <a href="https://publications.waset.org/abstracts/search?q=Nahla%20Abdelmoneim%20Hamid"> Nahla Abdelmoneim Hamid</a>, <a href="https://publications.waset.org/abstracts/search?q=Hazem%20Farag%20Manaa"> Hazem Farag Manaa</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Background: Chronic myeloid leukemia (CML) represents 15% of adult leukemias. Imatinib Mesylate (IM) is the gold standard treatment for new cases of CML. Treatment with IM results in improvement of the majority of cases. However, about 25% of cases may develop resistance. Sensitive and specific early predictors of IM resistance in CML patients have not been established to date. Aim: To investigate the value of miR-451 in CML as an early predictor for IM resistance in Egyptian CML patients. Methods: The study employed Real time Polymerase Reaction (qPCR) technique to investigate the leucocytic expression of miR-451 in fifteen newly diagnosed CML patients (group I), fifteen IM responder CML patients (group II), fifteen IM resistant CML patients (group III) and fifteen healthy subjects of matched age and sex as a control group (group IV). The response to IM was defined as < 10% BCR-ABL transcript level after 3 months of therapy. The following parameters were assessed in subjects of all the studied groups: 1- Complete blood count (CBC). 2- Measurement of plasma level of miRNA 451 using real-time Polymerase Chain Reaction (qPCR). 3- Detection of BCR-ABL gene mutation in CML using qPCR. Results: The present study revealed that miR-451 was significantly down-regulated in leucocytes of newly diagnosed CML patients as compared to healthy subjects. IM responder CML patients showed an up-regulation of miR- 451 compared with IM resistant CML patients. Conclusion: According to the data from the present study, it can be concluded that leucocytic miR- 451 expression is a useful additional follow-up marker for the response to IM and a promising prognostic biomarker for CML. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20myeloid%20leukemia" title="chronic myeloid leukemia">chronic myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=imatinib%20resistance" title=" imatinib resistance"> imatinib resistance</a>, <a href="https://publications.waset.org/abstracts/search?q=microRNA%20451" title=" microRNA 451"> microRNA 451</a>, <a href="https://publications.waset.org/abstracts/search?q=Polymerase%20Chain%20Reaction" title=" Polymerase Chain Reaction"> Polymerase Chain Reaction</a> </p> <a href="https://publications.waset.org/abstracts/23100/the-predictive-value-of-micro-rna-451-on-the-outcome-of-imatinib-treatment-in-chronic-myeloid-leukemia-patients" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/23100.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">294</span> </span> </div> </div> <div class="card paper-listing mb-3 mt-3"> <h5 class="card-header" style="font-size:.9rem"><span class="badge badge-info">58</span> Mechanism of Modeling the Level of Bcr-Abl Oncoprotein by Ubiquitin-Proteasome System in Chronic Myeloid Leukemia</h5> <div class="card-body"> <p class="card-text"><strong>Authors:</strong> <a href="https://publications.waset.org/abstracts/search?q=Svitlana%20Antonenko">Svitlana Antonenko</a>, <a href="https://publications.waset.org/abstracts/search?q=Gennady%20Telegeev"> Gennady Telegeev</a> </p> <p class="card-text"><strong>Abstract:</strong></p> Introductive statement: The development of chronic myeloid leukemia (CML) is caused by Bcr-Abl oncoprotein. Modern treatments with tyrosine kinase inhibitors are greatly complicated by the mutational variability of the Bcr-Abl oncoprotein, which causes drug resistance. Therefore, there is an urgent need to develop new approaches to the treatment of the disease, which will allow modeling the level of Bcr-Abl oncoprotein in the cell. Promising in this direction is the identification of proteases that can selectively promote cellular proteolysis of oncoproteins. The aim of the study was to study the effect of the interaction of Bcr-Abl with deubiquitinase USP1 on the level of oncoprotein in CML cells. Methodology: K562 cells were selected for the experiment. Сells were incubated with ML323 inhibitor for 24 hours. Precipitation of endogenous proteins from K562 cell lysate was performed using anti-Bcr-Abl antibodies. Cell lysates and precipitation results were studied by Western blot. Subcellular localization of proteins was studied by immunofluorescence analysis followed by confocal microscopy. The results were analyzed quantitatively and statistically. Major findings: The Bcr-Abl/USP1 protein complex was detected in CML cells, and it was found that inhibition of USP1 deubiquitinating activity by the compound ML323 leads to disruption of this protein complex and a decrease in the level of Bcr-Abl oncoprotein in cells. The interaction of Bcr-Abl with USP1 may result in deubiquitination of the oncoprotein, which disrupts its proteasomal degradation and leads to the accumulation of CML in cells. Conclusion: We believe that the interaction of oncoprotein with USP1 may be one of the prerequisites that contribute to malignant cell transformation due to the deubiquitination of oncoprotein, which leads to its accumulation and disease progression. A correlation was found between the deubiquitinating activity of USP1 and the level of oncoprotein in CML cells. Thus, we identify deubiquitinase USP1 as a promising therapeutic target for the development of a new strategy for the treatment of CML by modulating the level of Bcr-Abl in the cell. <p class="card-text"><strong>Keywords:</strong> <a href="https://publications.waset.org/abstracts/search?q=chronic%20myeloid%20leukemia" title="chronic myeloid leukemia">chronic myeloid leukemia</a>, <a href="https://publications.waset.org/abstracts/search?q=Bcr-Abl" title=" Bcr-Abl"> Bcr-Abl</a>, <a href="https://publications.waset.org/abstracts/search?q=USP1" title=" USP1"> USP1</a>, <a href="https://publications.waset.org/abstracts/search?q=deubiquitination%20Bcr-Abl" title=" deubiquitination Bcr-Abl"> deubiquitination Bcr-Abl</a>, <a href="https://publications.waset.org/abstracts/search?q=K562%20cell" title=" K562 cell"> K562 cell</a> </p> <a href="https://publications.waset.org/abstracts/149255/mechanism-of-modeling-the-level-of-bcr-abl-oncoprotein-by-ubiquitin-proteasome-system-in-chronic-myeloid-leukemia" class="btn btn-primary btn-sm">Procedia</a> <a href="https://publications.waset.org/abstracts/149255.pdf" target="_blank" class="btn btn-primary btn-sm">PDF</a> <span class="bg-info text-light px-1 py-1 float-right rounded"> Downloads <span class="badge badge-light">69</span> </span> </div> </div> <ul class="pagination"> <li class="page-item disabled"><span class="page-link">&lsaquo;</span></li> <li class="page-item active"><span class="page-link">1</span></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=leukemia&page=2">2</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=leukemia&page=3">3</a></li> <li class="page-item"><a class="page-link" href="https://publications.waset.org/abstracts/search?q=leukemia&page=2" rel="next">&rsaquo;</a></li> </ul> </div> </main> <footer> <div id="infolinks" class="pt-3 pb-2"> <div class="container"> <div style="background-color:#f5f5f5;" class="p-3"> <div class="row"> <div class="col-md-2"> <ul class="list-unstyled"> About <li><a href="https://waset.org/page/support">About Us</a></li> <li><a href="https://waset.org/page/support#legal-information">Legal</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/WASET-16th-foundational-anniversary.pdf">WASET celebrates its 16th foundational anniversary</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Account <li><a href="https://waset.org/profile">My Account</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Explore <li><a href="https://waset.org/disciplines">Disciplines</a></li> <li><a href="https://waset.org/conferences">Conferences</a></li> <li><a href="https://waset.org/conference-programs">Conference Program</a></li> <li><a href="https://waset.org/committees">Committees</a></li> <li><a href="https://publications.waset.org">Publications</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Research <li><a href="https://publications.waset.org/abstracts">Abstracts</a></li> <li><a href="https://publications.waset.org">Periodicals</a></li> <li><a href="https://publications.waset.org/archive">Archive</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Open Science <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Philosophy.pdf">Open Science Philosophy</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Science-Award.pdf">Open Science Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Open-Society-Open-Science-and-Open-Innovation.pdf">Open Innovation</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Postdoctoral-Fellowship-Award.pdf">Postdoctoral Fellowship Award</a></li> <li><a target="_blank" rel="nofollow" href="https://publications.waset.org/static/files/Scholarly-Research-Review.pdf">Scholarly Research Review</a></li> </ul> </div> <div class="col-md-2"> <ul class="list-unstyled"> Support <li><a href="https://waset.org/page/support">Support</a></li> <li><a href="https://waset.org/profile/messages/create">Contact Us</a></li> <li><a href="https://waset.org/profile/messages/create">Report Abuse</a></li> </ul> </div> </div> </div> </div> </div> <div class="container text-center"> <hr style="margin-top:0;margin-bottom:.3rem;"> <a href="https://creativecommons.org/licenses/by/4.0/" target="_blank" class="text-muted small">Creative Commons Attribution 4.0 International License</a> <div id="copy" class="mt-2">© 2024 World Academy of Science, Engineering and Technology</div> </div> </footer> <a href="javascript:" id="return-to-top"><i class="fas fa-arrow-up"></i></a> <div class="modal" id="modal-template"> <div class="modal-dialog"> <div class="modal-content"> <div class="row m-0 mt-1"> <div class="col-md-12"> <button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button> </div> </div> <div class="modal-body"></div> </div> </div> </div> <script src="https://cdn.waset.org/static/plugins/jquery-3.3.1.min.js"></script> <script src="https://cdn.waset.org/static/plugins/bootstrap-4.2.1/js/bootstrap.bundle.min.js"></script> <script src="https://cdn.waset.org/static/js/site.js?v=150220211556"></script> <script> jQuery(document).ready(function() { /*jQuery.get("https://publications.waset.org/xhr/user-menu", function (response) { jQuery('#mainNavMenu').append(response); });*/ jQuery.get({ url: "https://publications.waset.org/xhr/user-menu", cache: false }).then(function(response){ jQuery('#mainNavMenu').append(response); }); }); </script> </body> </html>